Randomized, double-blind, positive drug parallel control, multi-center Chinese medicine variety protection clinical trial on the efficacy and safety of Baihe Gujin tablet in the treatment of chronic pharyngitis (lung-kidney yin deficiency syndrome)

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University0 sitesTBD

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

3 years ago

Study Type

Observational study

Sex

All

Investigators

Sponsor

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

Eligibility Criteria

Inclusion Criteria

•(1\) Meet the diagnostic criteria for chronic pharyngitis;
•(2\) Comply with the standard of TCM syndrome differentiation of lung and kidney yin deficiency;
•(3\) Age 18 to 65 years old (including 18 and 65 years old), gender is not limited;
•(4\) Subjects gave informed consent, voluntarily tested and signed the informed consent form.

Exclusion Criteria

•(1\) Pharyngeal paraesthesia caused by chronic tonsillitis, styloid process syndrome, hyoid syndrome or other pharyngeal diseases, reflux esophagitis, bronchitis, early esophageal cancer, etc.;
•(2\) ALT and/or AST \>1\.5 upper limit of normal reference value; serum creatinine \> upper limit of normal reference value; blood leukocyte \<3\.0×109/L or \>10\.0×109/L; and/or neutrophil (N) classification \>80%; body temperature \=37\.3?;
•(3\) Patients who smoked or quit smoking for less than three months; or unavoidably exposed to dust or harmful gas for a long time;
•(4\) Those who have used drugs, non\-drug treatments or health products that have a therapeutic effect on chronic pharyngitis within 1 week; or who have received pharyngeal surgery within 6 months;
•(5\) Combined with serious primary diseases of cardiovascular and cerebrovascular, liver, kidney, respiratory system, circulatory system, autoimmune system and hematopoietic system, or serious diseases that affect their survival, such as tumor or AIDS; of disabled patients;
•(6\) A history of alcohol and drug abuse or drug use in the past year;
•(7\) Pregnant or lactating women or those who are unwilling to take contraceptive measures during the test and within 1 month after the end of the test;
•(8\) Participated in another drug study within three months prior to enrollment;
•(9\) Those with allergic constitution or known ingredients of the drug;
•(10\)The investigators determined that there were other factors that were inappropriate for enrollment.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting

Phase 4

Randomized, double-blind, positive drug parallel control, multi-center Chinese medicine variety protection clinical trial on the efficacy and safety of Baihe Gujin tablet in the treatment of post-cold cough (lung-kidney yin deficiency syndrome).cough after a cold

ITMCTR2200006021Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

Not yet recruiting

Phase 4

Randomized, double-blind, positive-drug parallel-controlled, multi-center clinical trial on the efficacy and safety of Baihe Gujin tablets in the treatment of cough caused by bronchiectasis (lung-kidney yin deficiency syndrome)Cough due to bronchiectasis

ITMCTR2200005979Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

Not yet recruiting

Phase 4

A randomized, double-blind, positive-drug, parallel-controlled multi-center clinical trial of the efficacy and safety of Chaishi Tuire granules for influenza.(RADICAL)Influenza

ITMCTR1900002740China-Japan Friendship Hospital

Active, not recruiting

Not Applicable

Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily as calibrator, for 12 months treatment, in patients with mild to moderate hypertension - RAVEL-1

EUCTR2005-003521-13-DEAventis Pharmaceuticals Inc.1,730

Active, not recruiting

Not Applicable

Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily as calibrator, for 12 months treatment, in patients with mild to moderate hypertensio

EUCTR2005-003521-13-PTAventis Pharmaceuticals Inc.1,730